Outcome of ICSI in HIV-1-infected women

BACKGROUND: Since 2001, French law has permitted the use of assisted reproductive technology in human immunodeficiency virus (HIV)-1 infected women under strict conditions. This report describes a preliminary series of seropositive women who underwent assisted reproduction treatment at our facility....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human reproduction (Oxford) 2005-10, Vol.20 (10), p.2838-2843
Hauptverfasser: Terriou, P., Auquier, P., Chabert-Orsini, V., Chinchole, J.M., Cravello, L., Giorgetti, C., Halfon, P., Salzmann, J., Roulier, R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2843
container_issue 10
container_start_page 2838
container_title Human reproduction (Oxford)
container_volume 20
creator Terriou, P.
Auquier, P.
Chabert-Orsini, V.
Chinchole, J.M.
Cravello, L.
Giorgetti, C.
Halfon, P.
Salzmann, J.
Roulier, R.
description BACKGROUND: Since 2001, French law has permitted the use of assisted reproductive technology in human immunodeficiency virus (HIV)-1 infected women under strict conditions. This report describes a preliminary series of seropositive women who underwent assisted reproduction treatment at our facility. To minimize contamination of culture media, equipment, and therefore of male gametes and embryos, we chose to perform ICSI in all cases. The outcome of ICSI was compared with the outcome in an age-matched group of non-HIV-1-infected women. Since several previous reports have indicated that HIV infection may be associated with a decrease in spontaneous fertility, our goal was also to assess the fertility status of the HIV-1-infected women entering our ICSI programme. METHODS: The French law governing the use of assisted reproduction protocols in HIV-1-infected women was strictly applied. The inclusion criteria were absence of ongoing disease, CD4(+) count >200 cells/mm3, and stable HIV-1 RNA level. Since mean age at the time of ICSI was higher in HIV-1-infected women than in the overall group of non-HIV-infected women, we compared outcome data in HIV-1-infected women (group I) to a group of non-HIV-1-infected women matched with regard to age and follicle retrieval period (group II) as well as to the overall group of women who underwent ICSI at our institution (group III). RESULTS: A total of 66 ovarian stimulations was performed in 29 HIV-1-infected-infected women. The percentage of cancelled cycles was higher in infected women than in matched controls (15.2 versus 4.9%, P < 0.05). The duration of ovarian stimulation (13.3 versus 11.7 days, P < 0.05) and amount of recombinant FSH injected (2898 versus 2429 IU, P < 0.001) were also higher in infected women. The number of retrieved oocytes, mature oocytes, and embryos obtained as well as embryo quality was similar in all groups. The fertilization rate was higher in infected women than in matched controls (67 versus 60%, P < 0.01). The pregnancy rate was not significantly different between groups I and II (16.1 versus 19.6%) in spite of the fact that the number of embryos transferred was purposefully restricted in the HIV-1-infected group to minimize multiple pregnancy (2.0 versus 2.4, not significant). CONCLUSION: The results of this preliminary series of ICSI cycles in HIV-1-infected women indicate that optimal ovarian stimulation is slightly more difficult to achieve than in matched seronegative women. However,
doi_str_mv 10.1093/humrep/dei119
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68607440</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/humrep/dei119</oup_id><sourcerecordid>915648241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-103113fc11f5adf29549dca3deab40cfcb154b04c2f271c40c1f20317ed120ca3</originalsourceid><addsrcrecordid>eNqF0M9L7DAQB_Agiu5bPXqVIujzUp1J0rQ96r6nu6AI_kK8hGyaYHXbrkmL-t8baVHw4ikh-WRm8iVkG-EQIWdHj13lzPKoMCVivkJGyAXElCWwSkZARRYjCtwgf7x_AgjbTKyTDUzyDADSEfl72bW6qUzU2Gg2uZ5FZR1NZ3cxxmVtjW5NEb2G63qTrFm18GZrWMfk9vT_zWQan1-ezSbH57HmCbQxAkNkViPaRBWW5gnPC61YYdScg7Z6jgmfA9fU0hR1OEJLw5vUFEghwDHZ7-suXfPSGd_KqvTaLBaqNk3npcgEpJzDrxDzjEFKRYC7P-BT07k6fEJSxCwPFXlAcY-0a7x3xsqlKyvl3iWC_MxZ9jnLPufgd4ai3bwyxbcegg1gbwDKa7WwTtW69N8uDTkI9tn4oHdNt_y15zBj6Vvz9oWVe5YiZWkip_cP8mL67-r-5G4iH9gH1e2hQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>211896864</pqid></control><display><type>article</type><title>Outcome of ICSI in HIV-1-infected women</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Terriou, P. ; Auquier, P. ; Chabert-Orsini, V. ; Chinchole, J.M. ; Cravello, L. ; Giorgetti, C. ; Halfon, P. ; Salzmann, J. ; Roulier, R.</creator><creatorcontrib>Terriou, P. ; Auquier, P. ; Chabert-Orsini, V. ; Chinchole, J.M. ; Cravello, L. ; Giorgetti, C. ; Halfon, P. ; Salzmann, J. ; Roulier, R.</creatorcontrib><description>BACKGROUND: Since 2001, French law has permitted the use of assisted reproductive technology in human immunodeficiency virus (HIV)-1 infected women under strict conditions. This report describes a preliminary series of seropositive women who underwent assisted reproduction treatment at our facility. To minimize contamination of culture media, equipment, and therefore of male gametes and embryos, we chose to perform ICSI in all cases. The outcome of ICSI was compared with the outcome in an age-matched group of non-HIV-1-infected women. Since several previous reports have indicated that HIV infection may be associated with a decrease in spontaneous fertility, our goal was also to assess the fertility status of the HIV-1-infected women entering our ICSI programme. METHODS: The French law governing the use of assisted reproduction protocols in HIV-1-infected women was strictly applied. The inclusion criteria were absence of ongoing disease, CD4(+) count &gt;200 cells/mm3, and stable HIV-1 RNA level. Since mean age at the time of ICSI was higher in HIV-1-infected women than in the overall group of non-HIV-infected women, we compared outcome data in HIV-1-infected women (group I) to a group of non-HIV-1-infected women matched with regard to age and follicle retrieval period (group II) as well as to the overall group of women who underwent ICSI at our institution (group III). RESULTS: A total of 66 ovarian stimulations was performed in 29 HIV-1-infected-infected women. The percentage of cancelled cycles was higher in infected women than in matched controls (15.2 versus 4.9%, P &lt; 0.05). The duration of ovarian stimulation (13.3 versus 11.7 days, P &lt; 0.05) and amount of recombinant FSH injected (2898 versus 2429 IU, P &lt; 0.001) were also higher in infected women. The number of retrieved oocytes, mature oocytes, and embryos obtained as well as embryo quality was similar in all groups. The fertilization rate was higher in infected women than in matched controls (67 versus 60%, P &lt; 0.01). The pregnancy rate was not significantly different between groups I and II (16.1 versus 19.6%) in spite of the fact that the number of embryos transferred was purposefully restricted in the HIV-1-infected group to minimize multiple pregnancy (2.0 versus 2.4, not significant). CONCLUSION: The results of this preliminary series of ICSI cycles in HIV-1-infected women indicate that optimal ovarian stimulation is slightly more difficult to achieve than in matched seronegative women. However, when criteria for oocyte retrieval were fulfilled, ICSI results were similar to those of age-matched controls.</description><identifier>ISSN: 0268-1161</identifier><identifier>EISSN: 1460-2350</identifier><identifier>DOI: 10.1093/humrep/dei119</identifier><identifier>PMID: 15980007</identifier><identifier>CODEN: HUREEE</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; AIDS ; Biological and medical sciences ; Case-Control Studies ; CD4-Positive T-Lymphocytes - metabolism ; Female ; fertility ; HIV ; HIV - metabolism ; HIV Infections - complications ; HIV Seropositivity ; Human immunodeficiency virus 1 ; Human viral diseases ; Humans ; ICSI ; Infectious diseases ; IVF ; Male ; Medical sciences ; Oocytes - metabolism ; Ovulation Induction ; Pregnancy ; Pregnancy Complications, Infectious ; Pregnancy Rate ; Pregnancy, High-Risk ; RNA - metabolism ; RNA, Viral - chemistry ; Sperm Injections, Intracytoplasmic - legislation &amp; jurisprudence ; Sperm Injections, Intracytoplasmic - methods ; Treatment Outcome ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; women</subject><ispartof>Human reproduction (Oxford), 2005-10, Vol.20 (10), p.2838-2843</ispartof><rights>The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org 2005</rights><rights>2005 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Oct 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-103113fc11f5adf29549dca3deab40cfcb154b04c2f271c40c1f20317ed120ca3</citedby><cites>FETCH-LOGICAL-c450t-103113fc11f5adf29549dca3deab40cfcb154b04c2f271c40c1f20317ed120ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17154634$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15980007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Terriou, P.</creatorcontrib><creatorcontrib>Auquier, P.</creatorcontrib><creatorcontrib>Chabert-Orsini, V.</creatorcontrib><creatorcontrib>Chinchole, J.M.</creatorcontrib><creatorcontrib>Cravello, L.</creatorcontrib><creatorcontrib>Giorgetti, C.</creatorcontrib><creatorcontrib>Halfon, P.</creatorcontrib><creatorcontrib>Salzmann, J.</creatorcontrib><creatorcontrib>Roulier, R.</creatorcontrib><title>Outcome of ICSI in HIV-1-infected women</title><title>Human reproduction (Oxford)</title><addtitle>Hum. Reprod</addtitle><addtitle>Hum. Reprod</addtitle><description>BACKGROUND: Since 2001, French law has permitted the use of assisted reproductive technology in human immunodeficiency virus (HIV)-1 infected women under strict conditions. This report describes a preliminary series of seropositive women who underwent assisted reproduction treatment at our facility. To minimize contamination of culture media, equipment, and therefore of male gametes and embryos, we chose to perform ICSI in all cases. The outcome of ICSI was compared with the outcome in an age-matched group of non-HIV-1-infected women. Since several previous reports have indicated that HIV infection may be associated with a decrease in spontaneous fertility, our goal was also to assess the fertility status of the HIV-1-infected women entering our ICSI programme. METHODS: The French law governing the use of assisted reproduction protocols in HIV-1-infected women was strictly applied. The inclusion criteria were absence of ongoing disease, CD4(+) count &gt;200 cells/mm3, and stable HIV-1 RNA level. Since mean age at the time of ICSI was higher in HIV-1-infected women than in the overall group of non-HIV-infected women, we compared outcome data in HIV-1-infected women (group I) to a group of non-HIV-1-infected women matched with regard to age and follicle retrieval period (group II) as well as to the overall group of women who underwent ICSI at our institution (group III). RESULTS: A total of 66 ovarian stimulations was performed in 29 HIV-1-infected-infected women. The percentage of cancelled cycles was higher in infected women than in matched controls (15.2 versus 4.9%, P &lt; 0.05). The duration of ovarian stimulation (13.3 versus 11.7 days, P &lt; 0.05) and amount of recombinant FSH injected (2898 versus 2429 IU, P &lt; 0.001) were also higher in infected women. The number of retrieved oocytes, mature oocytes, and embryos obtained as well as embryo quality was similar in all groups. The fertilization rate was higher in infected women than in matched controls (67 versus 60%, P &lt; 0.01). The pregnancy rate was not significantly different between groups I and II (16.1 versus 19.6%) in spite of the fact that the number of embryos transferred was purposefully restricted in the HIV-1-infected group to minimize multiple pregnancy (2.0 versus 2.4, not significant). CONCLUSION: The results of this preliminary series of ICSI cycles in HIV-1-infected women indicate that optimal ovarian stimulation is slightly more difficult to achieve than in matched seronegative women. However, when criteria for oocyte retrieval were fulfilled, ICSI results were similar to those of age-matched controls.</description><subject>Adult</subject><subject>AIDS</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>CD4-Positive T-Lymphocytes - metabolism</subject><subject>Female</subject><subject>fertility</subject><subject>HIV</subject><subject>HIV - metabolism</subject><subject>HIV Infections - complications</subject><subject>HIV Seropositivity</subject><subject>Human immunodeficiency virus 1</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>ICSI</subject><subject>Infectious diseases</subject><subject>IVF</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Oocytes - metabolism</subject><subject>Ovulation Induction</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious</subject><subject>Pregnancy Rate</subject><subject>Pregnancy, High-Risk</subject><subject>RNA - metabolism</subject><subject>RNA, Viral - chemistry</subject><subject>Sperm Injections, Intracytoplasmic - legislation &amp; jurisprudence</subject><subject>Sperm Injections, Intracytoplasmic - methods</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>women</subject><issn>0268-1161</issn><issn>1460-2350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0M9L7DAQB_Agiu5bPXqVIujzUp1J0rQ96r6nu6AI_kK8hGyaYHXbrkmL-t8baVHw4ikh-WRm8iVkG-EQIWdHj13lzPKoMCVivkJGyAXElCWwSkZARRYjCtwgf7x_AgjbTKyTDUzyDADSEfl72bW6qUzU2Gg2uZ5FZR1NZ3cxxmVtjW5NEb2G63qTrFm18GZrWMfk9vT_zWQan1-ezSbH57HmCbQxAkNkViPaRBWW5gnPC61YYdScg7Z6jgmfA9fU0hR1OEJLw5vUFEghwDHZ7-suXfPSGd_KqvTaLBaqNk3npcgEpJzDrxDzjEFKRYC7P-BT07k6fEJSxCwPFXlAcY-0a7x3xsqlKyvl3iWC_MxZ9jnLPufgd4ai3bwyxbcegg1gbwDKa7WwTtW69N8uDTkI9tn4oHdNt_y15zBj6Vvz9oWVe5YiZWkip_cP8mL67-r-5G4iH9gH1e2hQA</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>Terriou, P.</creator><creator>Auquier, P.</creator><creator>Chabert-Orsini, V.</creator><creator>Chinchole, J.M.</creator><creator>Cravello, L.</creator><creator>Giorgetti, C.</creator><creator>Halfon, P.</creator><creator>Salzmann, J.</creator><creator>Roulier, R.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20051001</creationdate><title>Outcome of ICSI in HIV-1-infected women</title><author>Terriou, P. ; Auquier, P. ; Chabert-Orsini, V. ; Chinchole, J.M. ; Cravello, L. ; Giorgetti, C. ; Halfon, P. ; Salzmann, J. ; Roulier, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-103113fc11f5adf29549dca3deab40cfcb154b04c2f271c40c1f20317ed120ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>AIDS</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>CD4-Positive T-Lymphocytes - metabolism</topic><topic>Female</topic><topic>fertility</topic><topic>HIV</topic><topic>HIV - metabolism</topic><topic>HIV Infections - complications</topic><topic>HIV Seropositivity</topic><topic>Human immunodeficiency virus 1</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>ICSI</topic><topic>Infectious diseases</topic><topic>IVF</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Oocytes - metabolism</topic><topic>Ovulation Induction</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious</topic><topic>Pregnancy Rate</topic><topic>Pregnancy, High-Risk</topic><topic>RNA - metabolism</topic><topic>RNA, Viral - chemistry</topic><topic>Sperm Injections, Intracytoplasmic - legislation &amp; jurisprudence</topic><topic>Sperm Injections, Intracytoplasmic - methods</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Terriou, P.</creatorcontrib><creatorcontrib>Auquier, P.</creatorcontrib><creatorcontrib>Chabert-Orsini, V.</creatorcontrib><creatorcontrib>Chinchole, J.M.</creatorcontrib><creatorcontrib>Cravello, L.</creatorcontrib><creatorcontrib>Giorgetti, C.</creatorcontrib><creatorcontrib>Halfon, P.</creatorcontrib><creatorcontrib>Salzmann, J.</creatorcontrib><creatorcontrib>Roulier, R.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Human reproduction (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Terriou, P.</au><au>Auquier, P.</au><au>Chabert-Orsini, V.</au><au>Chinchole, J.M.</au><au>Cravello, L.</au><au>Giorgetti, C.</au><au>Halfon, P.</au><au>Salzmann, J.</au><au>Roulier, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome of ICSI in HIV-1-infected women</atitle><jtitle>Human reproduction (Oxford)</jtitle><stitle>Hum. Reprod</stitle><addtitle>Hum. Reprod</addtitle><date>2005-10-01</date><risdate>2005</risdate><volume>20</volume><issue>10</issue><spage>2838</spage><epage>2843</epage><pages>2838-2843</pages><issn>0268-1161</issn><eissn>1460-2350</eissn><coden>HUREEE</coden><abstract>BACKGROUND: Since 2001, French law has permitted the use of assisted reproductive technology in human immunodeficiency virus (HIV)-1 infected women under strict conditions. This report describes a preliminary series of seropositive women who underwent assisted reproduction treatment at our facility. To minimize contamination of culture media, equipment, and therefore of male gametes and embryos, we chose to perform ICSI in all cases. The outcome of ICSI was compared with the outcome in an age-matched group of non-HIV-1-infected women. Since several previous reports have indicated that HIV infection may be associated with a decrease in spontaneous fertility, our goal was also to assess the fertility status of the HIV-1-infected women entering our ICSI programme. METHODS: The French law governing the use of assisted reproduction protocols in HIV-1-infected women was strictly applied. The inclusion criteria were absence of ongoing disease, CD4(+) count &gt;200 cells/mm3, and stable HIV-1 RNA level. Since mean age at the time of ICSI was higher in HIV-1-infected women than in the overall group of non-HIV-infected women, we compared outcome data in HIV-1-infected women (group I) to a group of non-HIV-1-infected women matched with regard to age and follicle retrieval period (group II) as well as to the overall group of women who underwent ICSI at our institution (group III). RESULTS: A total of 66 ovarian stimulations was performed in 29 HIV-1-infected-infected women. The percentage of cancelled cycles was higher in infected women than in matched controls (15.2 versus 4.9%, P &lt; 0.05). The duration of ovarian stimulation (13.3 versus 11.7 days, P &lt; 0.05) and amount of recombinant FSH injected (2898 versus 2429 IU, P &lt; 0.001) were also higher in infected women. The number of retrieved oocytes, mature oocytes, and embryos obtained as well as embryo quality was similar in all groups. The fertilization rate was higher in infected women than in matched controls (67 versus 60%, P &lt; 0.01). The pregnancy rate was not significantly different between groups I and II (16.1 versus 19.6%) in spite of the fact that the number of embryos transferred was purposefully restricted in the HIV-1-infected group to minimize multiple pregnancy (2.0 versus 2.4, not significant). CONCLUSION: The results of this preliminary series of ICSI cycles in HIV-1-infected women indicate that optimal ovarian stimulation is slightly more difficult to achieve than in matched seronegative women. However, when criteria for oocyte retrieval were fulfilled, ICSI results were similar to those of age-matched controls.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>15980007</pmid><doi>10.1093/humrep/dei119</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0268-1161
ispartof Human reproduction (Oxford), 2005-10, Vol.20 (10), p.2838-2843
issn 0268-1161
1460-2350
language eng
recordid cdi_proquest_miscellaneous_68607440
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
AIDS
Biological and medical sciences
Case-Control Studies
CD4-Positive T-Lymphocytes - metabolism
Female
fertility
HIV
HIV - metabolism
HIV Infections - complications
HIV Seropositivity
Human immunodeficiency virus 1
Human viral diseases
Humans
ICSI
Infectious diseases
IVF
Male
Medical sciences
Oocytes - metabolism
Ovulation Induction
Pregnancy
Pregnancy Complications, Infectious
Pregnancy Rate
Pregnancy, High-Risk
RNA - metabolism
RNA, Viral - chemistry
Sperm Injections, Intracytoplasmic - legislation & jurisprudence
Sperm Injections, Intracytoplasmic - methods
Treatment Outcome
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
women
title Outcome of ICSI in HIV-1-infected women
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T23%3A49%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20of%20ICSI%20in%20HIV-1-infected%20women&rft.jtitle=Human%20reproduction%20(Oxford)&rft.au=Terriou,%20P.&rft.date=2005-10-01&rft.volume=20&rft.issue=10&rft.spage=2838&rft.epage=2843&rft.pages=2838-2843&rft.issn=0268-1161&rft.eissn=1460-2350&rft.coden=HUREEE&rft_id=info:doi/10.1093/humrep/dei119&rft_dat=%3Cproquest_cross%3E915648241%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=211896864&rft_id=info:pmid/15980007&rft_oup_id=10.1093/humrep/dei119&rfr_iscdi=true